Clinical DevelopmentAbCellera began dosing the first participants in a Phase 1 study for its ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms associated with menopause after recently receiving regulatory authorization.
Financial PerformanceRevenues for the second quarter came in at $17.1 million as compared to $7.3 million in the prior year period, aided by a Trianni-license backed milestone payment.
Pipeline GrowthAbCellera announced plans to enter a third internal drug candidate, ABCL688, into IND-enabling studies, targeting the autoimmune therapeutic area.